Janus kinase (JAK) inhibitors are disease-modifying agents with efficacy in treating a
spectrum of burdensome dermatologic conditions. The US Food and Drug Administration …

Baricitinib is an oral, selective inhibitor of Janus kinase (JAK) 1/JAK2 that transiently and
reversibly inhibits many proinflammatory cytokines. This mechanism is a key mediator in a …

Importance The risk of venous thromboembolism (VTE) among patients with atopic
dermatitis (AD), especially when receiving treatment with Janus kinase (JAK) inhibitors, is …

Abstract Introduction Baricitinib, a Janus kinase (JAK) 1/2 inhibitor, is an approved treatment
for rheumatoid arthritis (RA), atopic dermatitis (AD), and alopecia areata (AA). Further …

Introduction Hidradenitis suppurativa (HS) is an autoinflammatory skin disease with a high
unmet need for effective medical management. Clinically, it is characterized by inflammatory …

Janus kinase (JAK) inhibitors are immunomodulatory agents with broad potential for use
within dermatology. However, the US Food and Drug Administration has recently placed …

Background Several studies have linked various chronic inflammatory skin diseases
(CISDs) with inflammatory bowel disease (IBD) in a range of data sources with mixed …

Vitiligo has been reported to be associated with a variety of diseases, but it has not been
systematically reviewed. Therefore, we aimed to identify prevalent diseases in patients with …

Background Atopic dermatitis (AD) may increase risk for atherothrombotic and
cardiovascular (CV) disease. Objective Determine CV disease and venous …

Background Atopic dermatitis (AD) is a common chronic inflammatory skin condition. While
other chronic inflammatory conditions are associated with increased risk of venous …